截至本公告披露日，公司已办理完成《公司章程》的备案手续。根据上海市市场监 督管理局的要求，本次备案的《公司章程》个别条款措辞有所调整，具体如下： | 调整前 | 调整后 | | --- | --- | | | 第八条 公司法定代表人由董事会选举的董 | | 第八条 董事长为公司的法定代表人。 | 事长（代表公司执行事务的董事）担任。 | | 董事长辞任的，视为同时辞去法定代表人。 | 董事长辞任的，视为同时辞去法定代表人。 | | 法定代表人辞任的，公司应当在法定代表人辞 | 法定代表人辞任的，公司应当在法定代表人辞 | | 任之日起三十日内确定新的法定代表人。 | 任之日起三十日内确定新的法定代表人。 | 证券代码：301230 证券简称：泓博医药 公告编号：2026-005 上海泓博智源医药股份有限公司 关于完成《公司章程》备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、基本情况 上海泓博智源医药股份有限公司（以下简称"公司"）分别于 2025 年 8 月 26 日、 2025 年 9 月 15 日召开了第四届董事会第三次会议、2025 年 ...

上海泓博智源医药股份有限公司 章 程 | 第一章 | 总 | 则 | 1 | | --- | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | | 第三章 | 股 | 份 | 3 | | 第四章 | 股东和股东会 | 7 | | | 第五章 | 董事和董事会 | 28 | | | 第六章 | 高级管理人员 | 42 | | | 第七章 | 财务会计制度、利润分配和审计 | 45 | | | 第八章 | 通知和公告 | 51 | | | 第一节 | 通 | 知 | 51 | | 第九章 | 合并、分立、增资、减资、解散和清算 | 52 | | --- | --- | --- | | 第十章 | 修改章程 | 56 | | 第十一章 | 附 则 | 57 | 第一章 总 则 公司由原上海泓博智源医药技术有限公司（以下简称"泓博有限"） 原登记在册的全体股东共同作为发起人，在泓博有限基础上，采取整 体变更的方式设立股份有限公司。 公司在上海市市场监督管理局注册登记，依法取得营业执照，统一社 会信用代码为 91310000669391074C。 公司中文名称：上海泓博智源医药股份有限 ...

业绩经营情况 公司已于2026年1月27日发布业绩预告，正式年报的发布将提供完整财务细节，包括各业务板块(如药物 发现、商业化生产)的具体表现。 公司状况 经济观察网截至2026年2月3日，泓博医药（301230）股价为48.85元/股，总市值约68.19亿元。公司近期 发布了2025年业绩预告，预计归母净利润为3120万元至3810万元，同比增长82.64%至123.03%。 行业政策与环境 医药行业在创新药支持、医保改革等政策背景下呈现结构性机会，但需注意集采、价格管控等风险。这 些因素可能间接影响公司长期战略。 机构持仓分析 银河基金、长城基金等机构产品重仓持有公司股票，显示市场关注度较高。机构行为可能反映对基本面 的预期，但需以公告为准。 以上内容基于公开资料整理，不构成投资建议。 公司2025年年报分红方案为每10股派现1元，股权登记日定于2026年1月12日。股权登记日已过，但派现 流程可能仍在进行中，需关注公司后续公告。 经营状况 公司于2026年1月14日公告股票交易出现严重异常波动(连续5日涨幅超100%)，并强调经营状况正常，但 DiOrion平台药物研发服务的直接收入占比较小。后续需关注 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for investment opportunities in this sector [10][64]. Core Insights - The medical services sector has shown resilience, with a recent increase in the sector's PE ratio to 34.43X and PB ratio to 3.49X, indicating a positive trend in valuation metrics [4][29]. - The approval of internet medical first diagnosis trials in Beijing marks a significant regulatory breakthrough, potentially accelerating the online medical service process and providing new market opportunities for private medical institutions [5][62][63]. - The report highlights the importance of digital regulation and standardization in enhancing service capabilities for private medical institutions, particularly in consumer healthcare sectors like pediatrics and dermatology [5][62]. Summary by Sections Industry Performance - The pharmaceutical and biological sector increased by 0.14%, ranking 15th among 31 primary industries, outperforming the Shanghai Composite Index by 1.47 percentage points [2][12]. - The medical services sub-sector reported a 1.31% increase, closing at 6827.17 points, with a year-to-date performance of 41.41% [24][27]. Company Performance - Top-performing companies in the medical services sector include Meidisi (+18.0%), Tongce Medical (+8.1%), and Nuosige (+5.7%), while underperformers include Haoyuan Pharmaceutical (-6.2%) and Baicheng Pharmaceutical (-4.5%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.56X from the previous week, while the PB ratio has risen by 0.06X, indicating a strengthening in market confidence [4][29]. Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and peptide CDMO in the pharmaceutical outsourcing sector, as well as companies like WuXi AppTec and Haoyuan Pharmaceutical [10][64]. - It also recommends monitoring private medical service providers with compliance experience, such as Aier Eye Hospital, as they are expected to benefit from the evolving regulatory landscape [5][64].

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，创业板医疗（970082）指数成份股当日主力资金净流入合计5628.7万元，游资资金净流 入合计1.24亿元，散户资金净流出合计1.81亿元。成份股资金流向详情见下表： 证券之星消息，2月5日，创业板医疗（970082）指数报收于3907.24点，跌0.29%，成交142.83亿元，换 手率1.99%。当日该指数成份股中，上涨的有16家，金凯生科以5.89%的涨幅领涨，下跌的有34家，泓 博医药以5.31%的跌幅领跌。 创业板医疗（970082）指数十大成份股详情如下： ...

证券之星消息，2月5日AI医疗板块较上一交易日下跌0.71%，泓博医药领跌。当日上证指数报收于 4075.92，下跌0.64%。深证成指报收于13952.71，下跌1.44%。AI医疗板块个股涨跌见下表： 从资金流向上来看，当日AI医疗板块主力资金净流出13.66亿元，游资资金净流入4.0亿元，散户资金净 流入9.66亿元。AI医疗板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券日报网讯2月4日，泓博医药（301230）在互动平台回答投资者提问时表示，截至2026年1月30日， 公司的股东户数为24614户。 ...

Market Performance - The medical services sector increased by 2.52% on February 3, with Norsig leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Top Gainers in Medical Services - Norsig (301333) closed at 78.98, up by 8.76% with a trading volume of 43,200 shares and a transaction value of 332 million [1] - Yinos (688710) closed at 61.07, up by 7.52% with a trading volume of 17,400 shares and a transaction value of 10.4 million [1] - Dean Diagnostics (300244) closed at 24.73, up by 6.69% with a trading volume of 447,200 shares and a transaction value of 1.084 billion [1] Market Capital Flow - The medical services sector saw a net inflow of 506 million from institutional investors, while retail investors experienced a net outflow of 4.12 billion [2][3] - The top stocks with significant institutional inflows included Tiger Medical (300347) with 103 million and Meinian Health (002044) with 86 million [3] Stock Performance Overview - The stock performance of various companies in the medical services sector showed a mix of gains and losses, with notable declines in stocks like Haocen Medical (002622) down by 1.97% [2] - The trading volume and transaction values varied significantly across different companies, indicating diverse investor interest [2]

2月3日，泓博医药涨5.14%，截至发稿，报48.85元/股，成交5.03亿元，换手率8.46%，总市值68.19亿 元。 截至发稿，龙宇飞累计任职时间8年111天，现任基金资产总规模7.04亿元，任职期间最佳基金回报 61.42%， 任职期间最差基金回报-8.9%。 从泓博医药十大流通股东角度 从基金十大重仓股角度 资料显示，上海泓博智源医药股份有限公司位于上海市浦东新区凯庆路59号12幢，成立日期2007年12月 14日，上市日期2022年11月1日，公司主营业务涉及药物发现、制药工艺的研究开发以及原料药中间体 的商业化生产。主营业务收入构成为：药物发现52.67%，商业化生产35.00%，工艺研究与开发8.10%， 其他(补充)4.23%。 数据显示，长城基金旗下1只基金位居泓博医药十大流通股东。长城消费增值混合A（200006）三季度 持有股数160.09万股，持股数量与上期相比不变，占流通股的比例为2.08%。根据测算，今日浮盈赚取 约382.62万元。 数据显示，长城基金旗下1只基金重仓泓博医药。长城消费增值混合A（200006）四季度减持10万股， 持有股数150.09万股，占基金净值比例为6. ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]